We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
-19.11%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$231M
AUM Growth
-$64.4M
Cap. Flow
-$948K
Cap. Flow %
-0.41%
Top 10 Hldgs %
97.81%
Holding
16
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
SPRB
Spruce Biosciences
SPRB
+$948K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$154M 66.52%
6,068,125
– –
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.69B
$21M 9.11%
1,025,000
– –
VRNA
3
DELISTED
Verona Pharma
VRNA
$16.1M 6.98%
1,115,352
– –
ELEV
4
DELISTED
Elevation Oncology
ELEV
$7.65M 3.31%
2,834,910
– –
NUVB icon
5
Nuvation Bio
NUVB
$2.2B
$7.42M 3.21%
2,541,009
– –
CMPS
6
Compass Pathways
CMPS
$1.53B
$5.83M 2.52%
964,500
– –
GLUE icon
7
Monte Rosa Therapeutics
GLUE
$1.4B
$5.51M 2.38%
1,472,331
– –
BMEA icon
8
Biomea Fusion
BMEA
$84.6M
$3.59M 1.56%
798,757
– –
PSTX
9
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$3.05M 1.32%
1,043,267
– –
CALC icon
10
CalciMedica
CALC
$15.8M
$2.06M 0.89%
521,114
– –
MRKR icon
11
Marker Therapeutics
MRKR
$18.8M
$1.71M 0.74%
314,286
– –
TECX
12
Tectonic Therapeutic
TECX
$529M
$1.39M 0.6%
84,148
– –
OKUR
13
OnKure Therapeutics
OKUR
$154M
$1.34M 0.58%
88,608
– –
ACRS icon
14
Aclaris Therapeutics
ACRS
$726M
$478K 0.21%
434,455
– –
VIRX
15
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$157K 0.07%
288,571
– –
SPRB
16
Spruce Biosciences
SPRB
$118M
– –
-16,073
Closed -$948K

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Aisling Capital Management held 16 positions worth $231M, down 22% from $295M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Aisling Capital Management's Q2 2024 filing shows 1 closed position. The largest sale was Spruce Biosciences, an estimated $948K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management fully exited Spruce Biosciences in Q2 2024, selling an estimated $948K.
  • Aisling Capital Management's ten largest holdings make up 98% of its $231M portfolio in Q2 2024.
  • Aisling Capital Management opened 0 new positions and closed 1 in Q2 2024.
  • Aisling Capital Management's portfolio value fell 22% quarter-over-quarter to $231M.

Based on Aisling Capital Management's 13F filing for Q2 2024, filed 8 Aug 2024.